Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Os-Sh1
- Development stage
- Preclinical
- Lead developer
- York University
- Modality
- Small Molecules
- Administration
- Parenteral
01
Overview
Os-Sh1 is a novel organometallic bis-amidine osmium complex developed as an anti-proliferative agent for the treatment of cancer. It was designed to overcome resistance associated with traditional platinum-based chemotherapies like cisplatin. Os-Sh1 exerts its cytotoxic effects by inducing G0/G1 cell cycle arrest and triggering the intrinsic mitochondrial pathway of apoptosis, evidenced by the cleavage of caspase-9, caspase-3, and poly-ADP ribose polymerase (PARP). In preclinical studies, it demonstrated superior potency compared to platinum drugs in endometrial and cervical cancer cell lines.
- Other names
- bis-amidine osmium complex
02
Targets
DNA
Beyond the preview
Go deeper on Os-Sh1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Os-Sh1.